比利时的非专利生物制品市场：医疗系统是否在给公平市场竞争制造障碍？
The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?
作者信息
Wilder Philippe Van
机构信息
Ecole de Santé Publique, Université Libre de Bruxelles (ULB), Brussels 1050, Belgium.
出版信息
Pharmaceuticals (Basel). 2021 Apr 10;14(4):352. doi: 10.3390/ph14040352.
Abstract
We investigated the off-patent biological market in Belgium from a policy maker's perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator's reach and to a concertation model with assessment and appraisal being mixed which results in poorly effective policy measures.
摘要
我们从政策制定者的角度，结合比利时的药品卫生体系，对该国非专利生物制品市场进行了调查。主要障碍包括短期预算重点、创新者的巨大影响力，以及评估和评价相结合的协调模式，这导致政策措施效果不佳。
相似文献
1
The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?比利时的非专利生物制品市场：医疗系统是否在给公平市场竞争制造障碍？
Pharmaceuticals (Basel). 2021 Apr 10;14(4):352. doi: 10.3390/ph14040352.
2
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.比利时的非专利生物药和生物类似药：市场格局分析
Front Pharmacol. 2021 Apr 19;12:644187. doi: 10.3389/fphar.2021.644187. eCollection 2021.
3
Biosimilars in Belgium: a proposal for a more competitive market.比利时的生物类似药：一个更具竞争力的市场的提案。
Acta Clin Belg. 2021 Dec;76(6):441-452. doi: 10.1080/17843286.2020.1761690. Epub 2020 May 13.
4
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study.比利时专利过期生物药品处方决策的决定因素：一项定性研究。
BMC Health Serv Res. 2022 Sep 29;22(1):1211. doi: 10.1186/s12913-022-08591-1.
5
Pharmaceutical policy regarding generic drugs in Belgium.比利时关于仿制药的药品政策。
Pharmacoeconomics. 2005;23(8):755-66. doi: 10.2165/00019053-200523080-00002.
6
The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.韩国新药定价政策对专利过期药物市场竞争的影响。
Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):1007-14. doi: 10.1586/14737167.2015.1083425. Epub 2015 Sep 22.
7
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?欧洲治疗性单克隆抗体专利概述：它们是否是生物类似药进入市场的障碍？
MAbs. 2020 Jan-Dec;12(1):1743517. doi: 10.1080/19420862.2020.1743517.
8
Incentives for market penetration of biosimilars in Belgium and in five European countries.比利时及五个欧洲国家生物类似药市场渗透的激励措施。
J Pharm Belg. 2014 Dec(4):36-46.
9
Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.生物类似药与专利促红细胞生成素：借鉴欧洲和日本五年经验
Appl Health Econ Health Policy. 2015 Feb;13(1):47-59. doi: 10.1007/s40258-014-0125-6.
10
Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.西班牙专利过期药品市场的竞争：全国参考定价体系与安达卢西亚地区门诊处方药招标制度的比较。
Health Policy. 2018 Dec;122(12):1310-1315. doi: 10.1016/j.healthpol.2018.10.008. Epub 2018 Oct 12.
引用本文的文献
1
The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis.政策干预对促进比利时生物类似药使用的影响：全国中断时间序列分析。
Health Res Policy Syst. 2023 Jul 6;21(1):68. doi: 10.1186/s12961-023-01015-4.
2
How to balance valuable innovation with affordable access to medicines in Belgium?如何在比利时平衡有价值的创新与民众负担得起的药品可及性？
Front Pharmacol. 2022 Sep 16;13:960701. doi: 10.3389/fphar.2022.960701. eCollection 2022.
3
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.比利时生物类似药的使用与转换：综合政策制定途径
Front Pharmacol. 2022 Jul 12;13:821616. doi: 10.3389/fphar.2022.821616. eCollection 2022.
4
Emerging Insights into European Markets of Biologics, Including Biosimilars.对欧洲生物制品市场（包括生物类似药）的新见解。
Pharmaceuticals (Basel). 2022 May 17;15(5):615. doi: 10.3390/ph15050615.
5
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.比利时门诊护理患者对生物类似药的认知
Front Pharmacol. 2022 Jan 5;12:789640. doi: 10.3389/fphar.2021.789640. eCollection 2021.
本文引用的文献
1
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.比利时的非专利生物药和生物类似药：市场格局分析
Front Pharmacol. 2021 Apr 19;12:644187. doi: 10.3389/fphar.2021.644187. eCollection 2021.
2
Belgium: Health System Review.比利时：卫生体系综述。
Health Syst Transit. 2020 Dec;22(5):1-237.
3
A health economic guide to market access of biosimilars.生物类似药市场准入的健康经济指南。
Expert Opin Biol Ther. 2021 Jan;21(1):9-17. doi: 10.1080/14712598.2021.1849132.
4
Biosimilars in Belgium: a proposal for a more competitive market.比利时的生物类似药：一个更具竞争力的市场的提案。
Acta Clin Belg. 2021 Dec;76(6):441-452. doi: 10.1080/17843286.2020.1761690. Epub 2020 May 13.
5
Economic evaluation of biosimilars for reimbursement purposes - what, when, how?用于报销目的的生物类似药的经济学评估——是什么、何时进行、如何开展？
J Mark Access Health Policy. 2020 Mar 15;8(1):1739509. doi: 10.1080/20016689.2020.1739509. eCollection 2020.
Zotero 插件